{"id":758545,"date":"2023-05-12T15:48:07","date_gmt":"2023-05-12T19:48:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/"},"modified":"2023-05-12T15:48:07","modified_gmt":"2023-05-12T19:48:07","slug":"cingulate-indegene-to-participate-in-benzinga-all-live-access-event","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/","title":{"rendered":"Cingulate, Indegene to Participate in Benzinga All Live Access Event"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">KANSAS CITY, Kan., May  12, 2023  (GLOBE NEWSWIRE) &#8212; Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release\u2122 (PTR\u2122) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman &amp; CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.<\/p>\n<p>The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oSuuRrZdk2zSVlfPzO2P8DX1UmQwU7LSYPI1tPpujVMmsU98FqgmjP92GsorTULcOvfC6FBiKq6mDHwwEKFo-Q==\" rel=\"nofollow noopener\" target=\"_blank\">Indegene<\/a>, a life sciences commercialization company, to provide commercial support for Cingulate\u2019s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit\/hyperactivity disorder (ADHD), upon approval from the U.S. Food and Drug Administration (FDA).<\/p>\n<p>The event may be viewed live on Benzinga\u2019s YouTube channel,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C5AglHWpDHpWNylqyerVCkaIjftce3OJ9mZJQKCcFv-vvCKITBT_vBn26vHNvRx-XekZvT21KdxYZjKmleL7FDKH72dsTINAseVEbjLQYjXKWZFp7hbBE-LTC3wquekC\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Benzinga All Access<\/strong><\/a>, and will also be available for viewing on Cingulate\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X0XD10ChQUHNcs-qu9U7kJk9CWi0OjrprA7zXhkvDHhCSk5Sp6d80Kisn7kjXBGKAqhO9VaSQzXdViB-txKNRP8P67WAvohPO4mgNmMyEmiLskCkYTA4S775URlXIV55T_HlntlAtKKv-kE3mbNir3HyaebQ-wDtAwtUpx7embBY-BhWszvligEO_3_HUo5l4loDVn8vHIBKwtjoxrr9wAFiVzkW84yhUv9SuDwyCCdrgoXgoRIOZrY9Qa-wr2ONA3urM78Lwe5qJfh9tuzVQkysl3ft29Tk5oq4ozGHgwKEfRolKH-g_v37VagbMsHA\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>cingulate.com\/investors<\/u><\/strong><\/a>.<\/p>\n<p>\n        <strong>About Cingulate<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae\u00a0<\/strong><br \/>\n        <\/sup><br \/>\n        <br \/>Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release\u2122 (PTR\u2122) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit\/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P7xX9k8LH8i7XJvyIE7llAFLoIaxBlRxq4rqLI3rHjFqRCU5jU7FQcVt7ZGhqgqEAY7O3ZZb3rc-mqU34jXDLLuFSE62i5rOAZ-YBHQgh2HHzaqB_JL9e7vbjweM9JICPHo61Qoe-3ExdoVAxtacPMmUTCfkMMNRuokZMm-1BsSZLuoR_UExhbxfrkL_jpQgoi0F0iTNA5alMov5NyPODp2v_1C79FEAFLdL45-F27I=\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>Cingulate.com<\/u><\/strong><\/a><\/p>\n<p>\n        <strong>About Indegene<\/strong><br \/>\n        <br \/>We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It\u2019s what drives our team and our purpose to enable healthcare organizations to be future ready. To learn more, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S6e1yqQLRDGqCKBZwj9G8Ctuk8ocjiu3bO7tcQmn0P8R2oBRAGf4g6OkxYK1kO2r1rLEDQoQQfmRqp3b9CGmKSjhBdn-8bR67MX0kwVPVJHqdlRH5fZwCkDO_dveLBE7gzlg4zkwYEqof5K3DsDwKjoOVuph6gmVhWeBMc9LGznoiAS2ZrjQuWDXX_WrwIEgEdfp-wntev1gzDetk0quZrZlKjsGELwX6uxywwSoihI=\" rel=\"nofollow noopener\" target=\"_blank\"><strong>www.indegene.com<\/strong><\/a><\/p>\n<p>\n        <strong>Investor Relations<\/strong>\u00a0<br \/>Thomas Dalton\u00a0<br \/>Vice President, Investor &amp; Public Relations, Cingulate<br \/>tdalton@cingulate.com<br \/>913-942-2301<\/p>\n<p>Matt Kreps<br \/>Darrow Associates<br \/>mkreps@darrowir.com<br \/>214-597-8200<\/p>\n<p>\n        <strong>Media Relations<\/strong><br \/>\n        <br \/>Melyssa Weible<br \/>Elixir Health Public Relations<br \/>mweible@elixirhealthpr.com<br \/>201-723-5805<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjEwN2QxZjEtYTczNC00M2ZhLTgyY2ItOTEyNWQ0Zjk1Njg5LTEyMjE3Nzg=\/tiny\/Cingulate-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release\u2122 (PTR\u2122) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman &amp; CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST. The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and\u00a0Indegene, a life sciences commercialization company, to provide commercial support for Cingulate\u2019s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit\/hyperactivity &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cingulate, Indegene to Participate in Benzinga All Live Access Event&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-758545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release\u2122 (PTR\u2122) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman &amp; CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST. The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and\u00a0Indegene, a life sciences commercialization company, to provide commercial support for Cingulate\u2019s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit\/hyperactivity &hellip; Continue reading &quot;Cingulate, Indegene to Participate in Benzinga All Live Access Event&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-12T19:48:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cingulate, Indegene to Participate in Benzinga All Live Access Event\",\"datePublished\":\"2023-05-12T19:48:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/\"},\"wordCount\":411,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/\",\"name\":\"Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\",\"datePublished\":\"2023-05-12T19:48:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cingulate, Indegene to Participate in Benzinga All Live Access Event\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/","og_locale":"en_US","og_type":"article","og_title":"Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk","og_description":"KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) &#8212; Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release\u2122 (PTR\u2122) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman &amp; CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST. The discussion will focus on the recent announcement of a joint commercialization agreement between Cingulate and\u00a0Indegene, a life sciences commercialization company, to provide commercial support for Cingulate\u2019s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment being developed as a true, once-daily stimulant medication for attention deficit\/hyperactivity &hellip; Continue reading \"Cingulate, Indegene to Participate in Benzinga All Live Access Event\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-12T19:48:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cingulate, Indegene to Participate in Benzinga All Live Access Event","datePublished":"2023-05-12T19:48:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/"},"wordCount":411,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/","name":"Cingulate, Indegene to Participate in Benzinga All Live Access Event - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=","datePublished":"2023-05-12T19:48:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzODU5MSM1NTkzMzEwIzIyMTAyMjU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cingulate-indegene-to-participate-in-benzinga-all-live-access-event\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cingulate, Indegene to Participate in Benzinga All Live Access Event"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=758545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/758545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=758545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=758545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=758545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}